SARS-CoV-2 Polymerase Chain Reaction Cycle Threshold Trends in Patients Who Are Immunocompromised and Implications for Isolation Precautions.

Among 495 patients who were immunocompromised and tested positive for SARS-CoV-2, polymerase chain reaction cycle thresholds remained <33 beyond 20 days more frequently in patients with hematologic malignancies, particularly those receiving B-cell-depleting or Bruton tyrosine kinase inhibitor therapy, as compared with those with solid organ malignancy (26% vs 5%).
Competing Interests: Potential conflicts of interest. M. K.: grants from Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Massachusetts Department of Public Health (MDPH) and royalties from UpToDate, none related to this study. C. R.: grants from Centers for Disease Control and Prevention and Agency for Healthcare Research and Quality unrelated to this study; royalties from UpToDate; payments from the Infectious Diseases Society of America for the role as associate editor for Clinical Infectious Diseases. M. A. B.: grants from Centers for Disease Control and Prevention. All other authors report no potential conflicts.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)